Tuesday, October 27, 2026

Why the Real Fix for U.S. Insulin Prices Was Hidden in Tax and Medicaid Rules

›
Sanofi's former "unbranded" version of Lantus Several years ago, all of the big branded insulin manufacturers in the U.S. had ...
Friday, October 16, 2026

MiniMed Go Could Turn Expiring InPen Users into Lost Customers

›
Back on July 27, 2016, a diabetes startup based in San Diego known as Companion Medical received FDA approval for a wireless-enabled insulin...
Friday, October 02, 2026

Dexcom Is Out. Libre Is In. I'm Happy, Except About the Prior Authorization (PA).

›
I recently received notice that my employer-sponsored Aetna healthcare plan will drop Dexcom CGMs from its formulary and adopt Abbott FreeSt...
1 comment:
Thursday, September 24, 2026

Why Reform Hasn't Reached the Pharmacy Counter Yet

›
Currently FDA approved Novolog biosimilars Since 2025, the FDA has approved THREE (3) biosimilar copies of Novolog (depicted in the image ab...
Saturday, August 29, 2026

The U.S. Prescription Drug Market Has Changed, But Our Assumptions About It Did Not

›
The way Americans buy prescription drugs has changed so much that many of the old assumptions we still rely on now have potential to work ag...
Tuesday, August 11, 2026

Breakthrough T1D's coup d'état of the T1D Fund's Board

›
Remember back in 2021 when the New York Times (see the article at https://www.nytimes.com/2021/07/02/your-money/philanthropy-type-1-diabete...
Monday, August 03, 2026

Meitheal Pharmaceuticals Announces FDA Approval of Garzulys™ (insulin aspart-fsan), Becoming the 3rd Insulin Aspart Biosimilar Approved

›
On July 24, 2026, there was news that Chicago-based Meitheal Pharmaceuticals had received FDA approval for another (the third approved as of...
Wednesday, June 10, 2026

The Most Lucrative Biosimilar Insulin Opportunity May Not Be the Biggest One

›
The race to develop biosimilar or follow-on biologic entrants in the U.S. insulin market has suffered from a fundamental strategic flaw: cha...